NCT01478555撤回2 期
A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Improvement in OSDI Scoring
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic solution) compared to Vehicle and DuraSite alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Volunteers 18 years of age and older who have a diagnosis of moderate to severe dry eye disease.
- •Negative pregnancy test prior to the conduct of any protocol-specific procedure. The subject must use effective contraception for the duration of the study. Post menopausal is defined as having no menses for at least 12 consecutive months
- •Signature of the subject on the Informed Consent Form
- •Willing to avoid disallowed medication for the duration of the study.
- •Able to self-administer study drug (or have a caregiver available to instill all doses of study drug)
- •Able and willing to follow study instructions
- •Additional inclusion criteria also apply
排除标准
- •Females who are pregnant or nursing. Females of childbearing potential (not surgically sterilized or postmenopausal) may not participate in the study if they do not agree to use adequate birth control methods for the duration of the study).
- •Use of contact lenses during the study.
- •Use of any concomitant topical ocular medications except for artificial tears during the dosing period
- •Presence or history of treatment with systemic immunosuppressive or chemotherapeutic agents.
- •Prior or anticipated concurrent use of an investigational product or device that could confound the findings about Dry Eye in the study eye.
- •A condition or a situation, which in the investigator's opinion may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation
- •Known hypersensitivity to any component of the study drug or procedural medications
- •Participation in any other clinical trial within 30 days prior to screening
- •Known hypersensitivity to NSAIDS
- •Any active corneal epithelial/stromal pathology noted in the study eye at the screening visit
- •Any history of corneal surgery (including corneal crosslinking, radial keratotomy, corneal transplant, or LASIK)
- •Cataract surgery within the past year.
- •Known contraindication to the study drugs or any of their components
研究组 & 干预措施
Dose 1 of Bromfenac in DuraSite
Experimental
干预措施: ISV 101 (Drug)
Dose 2 of Bromfenac in DuraSite
Experimental
干预措施: ISV 101 (Drug)
Dose 3 of Bromfenac in DuraSite
Experimental
干预措施: ISV 101 (Drug)
DuraSite
Active Comparator
干预措施: ISV 101 (Drug)
Vehicle
Active Comparator
干预措施: ISV 101 (Drug)
结局指标
主要结局
Improvement in OSDI Scoring
时间窗: Week 8
Improvement in Corneal Fluorescein Staining
时间窗: Week 8
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy SubjectsCicatrixRe-epithelialisationNCT00984854Renovo70
已完成
2 期
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye DiseaseDry Eye DiseaseNCT04084483Kowa Research Institute, Inc.238
撤回
2 期
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell CarcinomaSquamous Cell CarcinomaNCT00605709BPGbio
已完成
3 期
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaChronic UrticariaNCT04976192Teva Pharmaceuticals USA608
招募中
1 期
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaGlioblastomaNCT04443010Philogen S.p.A.226